20 results on '"Varker, Kimberly A."'
Search Results
2. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors
- Author
-
Varker, Kimberly A., Campbell, Jacqueline, and Shah, Manisha H.
- Published
- 2008
- Full Text
- View/download PDF
3. Repeat Transarterial Chemoembolization (TACE) for Progressive Hepatic Carcinoid Metastases Provides Results Similar to First TACE
- Author
-
Varker, Kimberly A., Martin, Edward W., Klemanski, Dori, Palmer, Bryan, Shah, Manisha H., and Bloomston, Mark
- Published
- 2007
- Full Text
- View/download PDF
4. A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma
- Author
-
Varker, Kimberly A., Biber, Jennifer E., Kefauver, Cheryl, Jensen, Rhonda, Lehman, Amy, Young, Donn, Wu, Haifeng, Lesinski, Gregory B., Kendra, Kari, Chen, Helen X., Walker, Michael J., and Carson III, William E.
- Published
- 2007
- Full Text
- View/download PDF
5. Release of Biologically Functional Interferon-Alpha from a Nanochannel Delivery System
- Author
-
Lesinski, Gregory B., Sharma, Sadhana, Varker, Kimberly A., Sinha, Piyush, Ferrari, Mauro, and Carson, III, William E.
- Published
- 2005
- Full Text
- View/download PDF
6. Salvage of Pelvic Recurrence of Colorectal Cancer
- Author
-
Varker, Kimberly A. and Wanebo, Harold J.
- Published
- 2010
- Full Text
- View/download PDF
7. Surgical Management of Pelvic Malignancy: Role of Extended Abdominoperineal Resection/Exenteration/Abdominal Sacral Resection
- Author
-
Wanebo, Harold J., Begossi, Giovanni, and Varker, Kimberly A.
- Published
- 2005
- Full Text
- View/download PDF
8. Radiofrequency Ablation of Hepatic Malignancies: The Surgeonʼs Perspective
- Author
-
Varker, Kimberly A. and Iannitti, David A.
- Published
- 2003
9. Pancreatectomy for non-pancreatic malignancies results in improved survival after R0 resection
- Author
-
Ellison Christopher, Wall Kristian, Muscarella Peter, Varker Kimberly A, and Bloomston Mark
- Subjects
Surgery ,RD1-811 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Pancreatectomy has a high morbidity but remains the only chance of cure for pancreatic cancer. Its efficacy for non-pancreatic malignancies is less clear. We reviewed our experience with pancreatectomy for non-pancreatic malignancies to determine outcomes and identify predictors of survival. Patients and methods The records of patients who underwent pancreatectomy for non-pancreatic malignancies between 1990 and 2005 were reviewed. Survival curves were constructed using the Kaplan-Meier method and compared using log-rank analysis. Cox proportional hazards was used to identify predictors of survival. Results 29 patients (18 M/11 F) with a mean age of 59.9 years (range 29–86) underwent pancreatectomy for non-pancreatic malignancies. 19 (66%) primary malignancies were GI in origin. Most operations were undertaken with curative intent (76%), whereas the remainder was for symptom palliation. Pancreatectomy was completed for metastatic disease in 7 patients (24%) or en bloc to achieve negative margins in 22 patients (76%). Complete (i.e., R0) resection was achieved in 17 (59%). Perioperative mortality was 3%. Median follow-up was 15 months (range 7–172). Median overall survival was 12 months with 1-year survival of 48%. Significant predictors of improved survival by univariate analysis were R0 resection, non-GI primary, and pancreatic metastasectomy (vs. en bloc resection). Only R0 resection was predictive of long-term survival by multivariate analysis (median 21 months vs. 6). Conclusion Pancreatic resection for non-pancreatic malignancies can be completed with minimal mortality. However, incomplete resection results in poor overall survival. Pancreatectomy for non-pancreatic malignancies should only be undertaken if complete resection is possible.
- Published
- 2007
- Full Text
- View/download PDF
10. Subphrenic and Pleural Abscess Due to Spilled Gallstones
- Author
-
Iannitti, David A., Varker, Kimberly A., Zaydfudim, Victor, and McKee, Jason
- Subjects
Male ,Complications of laparoscopic cholecystectomy ,Pleural Cavity ,Subphrenic Abscess ,Case Reports ,Abscess ,Postoperative Complications ,Cholecystectomy, Laparoscopic ,Drainage ,Humans ,Cholecystectomy ,Perihepatic abscess ,Retained gallstones ,Aged - Abstract
Background: A 70-year-old male approximately 3 years after laparoscopic cholecystectomy presented to his primary care physician with a 4-month history of generalized malaise. Methods: A workup included magnetic resonance imaging that revealed a perihepatic abscess. The patient underwent ultrasound-guided drainage, with the removal of 1400 mL of purulent fluid and placement of 2 drains. Computed tomographic scanning showed resolution, and he was discharged home on oral antibiotics. At 2-month follow-up, the patient was asymptomatic, denying any constitutional symptoms. However, abdominal computed tomographic scanning revealed recurrence of the abscess, which measured approximately 18x9x7.5 cm, with mass effect on the liver. The patient was placed on intravenous antibiotics and scheduled for operative drainage. The abdomen was entered with a right subcostal incision, and 900 mL of purulent fluid was drained. We also noted abscess erosion through the inferolateral aspect of the right diaphragm into the pleural space. The pleural abscess was loculated and isolated from the lung parenchyma. Palpation within the abscess cavity revealed 9 large gallstones. Following copious irrigation and debridement of necrotic tissue, 3 drains were placed and the incision was closed. Results: The patient had an uneventful recovery and was discharged home on postoperative day number 6. Follow-up imaging at 3 months demonstrated resolution of the collection. Conclusion: Spillage of gallstones is a complication of laparoscopic cholecystectomy, occurring in 6% to 16% of all cases. Retained stones rarely result in a problem, but when complications arise, aggressive surgical intervention is usually necessary.
- Published
- 2006
11. Review of Complementary and Alternative Medicine and Selected Nutraceuticals: Background for a Pilot Study on Nutrigenomic Intervention in Patients with Advanced Cancer.
- Author
-
Varker, Kimberly A., Ansel, Adam, Aukerman, Glen, and Carson, III, William E.
- Subjects
- *
ADJUVANT treatment of cancer , *FUNCTIONAL foods , *HOMEOPATHIC research , *NATUROPATHY , *ALTERNATIVE medicine - Abstract
As commonly defined, complementary and alternative medicine (CAM) is a broad category that includes biologically based practices, mind-body medicine, manipulative and bodybased practices, and energy medicine as well as complete medical systems such as naturopathy, homeopathy, Ayurvedic medicine, and traditional Chinese medicine. Several CAM methodologies show promise for the treatment of chronic conditions such as depression and pain disorders or have demonstrated effects upon the immune response in experimental studies. There is growing interest in the use of integrative medicine——the combination of CAM methodologies with a conventional medical approach——for the optimization of treatment of various cancers. The Ohio State University Center for Integrative Medicine has developed a specialized nutrigenomic protocol for integrative cancer care. The center uses a comprehensive nutritional and medical evaluation, including a panel of proinflammatory molecules and physiologic parameters, to guide a program of individualized dietary interventions. Dietary supplementation is a current focus of study, including: (1) Omega-3 fatty acids and B vitamins, which are thought to play important roles in immunomodulation; (2) Magnesium oxide, which has been shown to decrease inflammation and improve insulin resistance and lipid profiles; and (3) Cinnamon extract, which reportedly decreases serum glucose levels. This article presents a brief overview of CAM and integrative medicine and a discussion of the relevant nutraceuticals. [ABSTRACT FROM AUTHOR]
- Published
- 2012
12. Impaired Natural Killer Cell Lysis in Breast Cancer Patients with High Levels of Psychological Stress is Associated with Altered Expression of Killer Immunoglobin-Like Receptors
- Author
-
Varker, Kimberly A., Terrell, Catherine E., Welt, Marilyn, Suleiman, Samer, Thornton, Lisa, Andersen, Barbara L., and Carson, William E.
- Subjects
- *
CANCER patients , *KILLER cells , *CELL-mediated cytotoxicity , *CELL membranes - Abstract
Background: We previously reported that cancer-related psychological stress is associated with reduced natural killer (NK) cell lysis. We hypothesized that reduced NK cell cytotoxicity in patients with increased levels of stress would correlate with alterations in the expression of inhibitory NK cell receptors (killer immunoglobulin-like receptors, or KIRs). The specific aim of this study was to examine KIR expression in patients with high or low levels of psychologic stress and correlate alterations in KIR expression with NK cell function. Materials and Methods: Two hundred twenty-seven patients underwent baseline evaluation of cancer-related psychological stress and were randomized to psychosocial intervention versus observation. From this population, two groups were defined based on pretreatment measurements of NK lytic activity, stress levels, and the availability of cryopreserved peripheral blood mononuclear cells (PBMC). Group I (n = 9) had low stress by the Impact of Events Scale (IES), and high NK cell lysis at the 50:1 effector: target ratio (NK50 = 52–89%). Group II (n = 8) had high stress and low NK50 (27–52%). Lymphokine activated killer (LAK) activity, antibody dependent cellular cytotoxicity (ADCC), and expression of cytokine receptors, adhesion molecules, and killer immunoglobulin-like receptors (KIRs) were assessed in PBMC. Results: Incubation of PBMC with NK-stimulatory cytokines (IL-2, IL-12, or IL-15) led to significant increases in cytotoxic activity regardless of IES/NK50 scores. There were no significant group differences in NK cell surface expression of the IL-2 receptor components CD25 and CD122, antibody-dependent lysis of HER2/neu-positive SKBr3 cells treated with an anti-HER2/neu monoclonal antibody, expression of adhesion molecules (CD2, CD11a, CD18) and markers of activation (CD69), or expression of the KIRs CD158a, NKG2a, NKB1, and CD161. However, levels of CD158b were significantly higher in Group I after incubation in media alone or with IL-2, and CD94 expression was significantly lower in Group I after incubation with IL-2. Conclusions: In this study of a small subset of breast cancer patients chosen from a previous clinical trial of psychosocial intervention for breast cancer, impaired NK lysis in breast cancer patients with high levels of psychological stress was associated with alterations in surface expression of killer immunoglobulin-like receptors. However, immune effectors retained the ability to lyse antibody-coated targets and to initiate lymphokine-activated killer activity, irrespective of stress levels or baseline NK50. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
13. Involvement of the muscarinic acetylcholine receptor in inhibition of cell migration
- Author
-
Varker, Kimberly A. and Williams, Carol L.
- Subjects
- *
MUSCARINIC receptors , *CELL migration , *PROTEIN kinase C - Abstract
Activation of G protein-coupled receptors is known to stimulate cell migration, but receptor-mediated signals inhibiting cell migration have not been identified. We investigated the ability of transfected human M3 muscarinic acetylcholine receptors (mAChR) to regulate the migration of Chinese hamster ovary (CHO) cells. Single cells migrated on colloidal gold applied to fibronectin-coated plates, and videomicroscopy was used to measure cell spreading and migration. Activation of M3 mAChR with the agonist carbachol was found to inhibit cell migration, whereas direct activation of protein kinase C (PKC) with PMA was found to stimulate migration. The amount of cell adhesion and spreading was found to be equivalent for carbachol- and PMA-treated cells. Selective inactivation of conventional PKC isoforms with Go6976 (C24H18N4O) abolished the PMA-mediated increase in cell migration. In contrast, the mAChR-mediated decrease in migration was not altered by Go6976, but was abolished when both novel and conventional PKC isoforms were inactivated by calphostin C or chelerythrine. These findings suggest involvement of conventional PKC isoforms in the stimulation of migration and of novel PKC isoforms in the inhibition of migration. Carbachol- but not PMA-treated cells exhibited an elongated morphology reminiscent of migrating cells that cannot detach their trailing edges from the substratum. Similarly, carbachol-treated cells detached less readily from fibronectin than control or PMA-treated cells when integrin activity was diminished by the chelation of Ca2+ and Mg2+. Finally, the carbachol-induced diminution of cell detachment was preserved after inhibition of the conventional PKC isoforms with Go6976, but was abrogated by treatment with either calphostin C or chelerythrine. These findings suggest that mAChR activation diminishes the ability of cells to detach from the substratum, resulting in diminished migration. This is in contrast to the direct activation of PKC with PMA, which stimulates migration. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
14. Management of Empyema Cavity With the Vacuum-Assisted Closure Device.
- Author
-
Varker, Kimberly A. and Ng, Thomas
- Subjects
LUNG surgery ,THORACIC surgery ,OPERATIVE surgery ,FISTULA ,EMPYEMA - Abstract
Management of empyema after pulmonary resection remains a challenging problem. Along with mandatory drainage of the thoracic cavity and investigations to rule out bronchopleural fistula, a reliable method of thoracic cavity closure is needed. The open thoracic window and Eloesser flap techniques rarely represent definitive therapy. Muscle flap and thoracoplasty procedures may provide well-vascularized tissue to close bronchopleural fistula and obliterate the empyema cavity, but they are quite complex and involve significant patient morbidity. We report a case of empyema without bronchopleural fistula after lobectomy in which the vacuum-assisted closure device was used to achieve complete wound healing after open drainage. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
15. A pilot study of bevacizumab and interferon-α2b in ocular melanoma.
- Author
-
Guenterberg KD, Grignol VP, Relekar KV, Varker KA, Chen HX, Kendra KL, Olencki TE, and Carson WE 3rd
- Subjects
- Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized, Bevacizumab, Eye Neoplasms pathology, Female, Follow-Up Studies, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Liver Neoplasms secondary, Lung Neoplasms secondary, Male, Melanoma secondary, Middle Aged, Neoplasm Staging, Pilot Projects, Recombinant Proteins, Survival Rate, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Eye Neoplasms drug therapy, Liver Neoplasms drug therapy, Lung Neoplasms drug therapy, Melanoma drug therapy
- Abstract
Objectives: We hypothesized that administration of bevacizumab, a monoclonal antibody that neutralizes vascular endothelial growth factor, in combination with high-dose interferon-alpha2b (IFN-α2b), an inhibitor of basic fibroblast growth factor, would have clinical activity in patients with metastatic ocular melanoma., Methods: Patients with metastatic ocular melanoma received bevacizumab (15 mg/kg intravenously every 2 weeks) plus IFN-α2b (5 MU/m subcutaneously 3 times weekly for 2 weeks followed by a dose of 10 MU/m subcutaneously thereafter). Patients exhibiting a clinical response or stabilization of disease were treated until disease progression., Results: In this pilot study, 5 patients were treated (3 men, 2 women) with a mean age of 63.8 years (range, 53-71 years). Overall, the regimen was well-tolerated. The following adverse events were noted: grade 3 dyspnea (2 patients), grade 3 and 4 fatigue (2), grade 3 muscle weakness (1), grade 3 anorexia (1), grade 1 and 2 proteinuria (2), and grade 3 diarrhea (1). All adverse events resolved with a treatment holiday or dose reduction. One patient had reduction in tumor burden of 23% by Response Evaluation Criteria in Solid Tumors criteria and 2 patients had stabilization of disease lasting 28 and 36 weeks, respectively. Two patients failed to respond and progressed after 6 and 7 weeks of therapy., Conclusion: Bevacizumab and IFN-α2b were well tolerated in this patient population, and clinical activity was observed. Further study of high-dose IFN-α2b in combination with bevacizumab in this setting is warranted.
- Published
- 2011
- Full Text
- View/download PDF
16. G3139 (Genasense) in patients with advanced merkel cell carcinoma.
- Author
-
Shah MH, Varker KA, Collamore M, Zwiebel JA, Coit D, Kelsen D, and Chung KY
- Subjects
- Aged, Carcinoma, Merkel Cell pathology, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Skin Neoplasms pathology, Survival Rate, Carcinoma, Merkel Cell drug therapy, Oligonucleotides, Antisense therapeutic use, Skin Neoplasms drug therapy, Thionucleotides therapeutic use
- Abstract
Objectives: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine malignancy of the skin. Preclinical studies have identified up-regulation of the critical antiapoptosis gene bcl-2 in MCC. We conducted a multicenter phase II trial of the novel bcl-2 antisense agent (G3139, Genasense) in patients with advanced MCC., Methods: Twelve patients (9 men, 3 women) with histologically confirmed metastatic or regionally recurrent MCC were enrolled. Ten patients (83%) had received prior chemotherapy. Eight patients (67%) had Karnofsky performance status of 90 to 100. Patients received continuous IV infusion of G3139 (7 mg/kg/d) via central venous access in an outpatient setting for 14 days, followed by a 7-day rest period. Response was assessed at 6-week intervals. Patients were allowed to continue therapy until unacceptable toxicity or disease progression., Results: No objective responses were observed. The best response was stable disease in 3 patients and progressive disease in 9 patients. A median of 4 doses per patient (total 46 doses) was administered. Dose delays and/or reductions were required in 6 patients. One patient developed grade 4 lymphopenia. One patient developed grade 3 renal failure characterized by grade 3-elevated creatinine and grade 4 hyperkalemia. Other grade 3 events included cytopenia (n = 5), aspartate aminotransferase/alanine aminotranferease elevation (n = 3), hypophosphatemia (n = 2), and pain (n = 1). The most frequent grade 1 to 2 toxicities were elevated creatinine, ALT elevation, hypokalemia, lymphopenia, and fatigue., Conclusions: Bcl-2 antisense therapy (G3139) was well tolerated among patients with advanced MCC. Although probable antitumor activity was documented in 1 patient, no objective responses per Response Evaluation Criteria in Solid Tumors criteria were observed.
- Published
- 2009
- Full Text
- View/download PDF
17. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines.
- Author
-
Raig ET, Jones NB, Varker KA, Benniger K, Go MR, Biber JL, Lesinski GB, and Carson WE 3rd
- Subjects
- Cell Line, Tumor, Cell Proliferation drug effects, Humans, Interleukin-12 metabolism, Recombinant Proteins pharmacology, Vascular Endothelial Growth Factor A blood, Vascular Endothelial Growth Factor A metabolism, Interferon-alpha pharmacology, Melanoma metabolism, Skin Neoplasms metabolism, Vascular Endothelial Growth Factor A antagonists & inhibitors
- Abstract
Interferon-alpha (IFN-alpha) is employed in the treatment of malignant melanoma; however, it mediates regression of disease in only 10-15% of patients. Currently, its mechanism of action is uncharacterized. Low-dose IFN-alpha exerts anti-angiogenic effects when used in the treatment of life-threatening hemangiomas of infancy, suggesting anti-angiogenesis as a mechanism of action. IFN-alpha may exert its anti-tumor effect in the setting of advanced malignancy by inhibiting the secretion of vascular endothelial growth factor (VEGF), a pro-angiogenic substance. We hypothesized that IFN-alpha would decrease the release of VEGF by melanoma tumors. We studied the effect of IFN-alpha on VEGF production in nine human melanoma cell lines. We also examined VEGF levels in 49 patients with advanced malignancies who received low-dose IFN-alpha and interleukin-12 (IL-12) on an NCI-sponsored phase I trial. Human melanoma cell lines produced varying amounts of VEGF in vitro (60-1500 pg/mL at 48 h). Certain melanoma cell lines such as 18105 MEL secreted low levels of VEGF (152 pg/mL) after 48 h of culture, whereas other lines secreted very high levels (FO-1 3,802 pg/mL). Treatment of melanoma cells with IFN-alpha (2000 U/mL) decreased VEGF secretion by 40-60% in VEGF-high cell lines; however, this effect was not demonstrated in VEGF-low cell lines. In cancer patients, pretreatment VEGF plasma levels varied from 471 to 4200 pg/mL. A decrease in VEGF plasma levels after treatment directly correlated with the number of treatment cycles administered (Pearson correlation, p = 0.04). In summary, IFN-alpha inhibits VEGF secretion by melanoma cell lines in vitro and may have similar actions in malignancies that respond to IFN-alpha treatment.
- Published
- 2008
- Full Text
- View/download PDF
18. Pancreatectomy for non-pancreatic malignancies results in improved survival after R0 resection.
- Author
-
Varker KA, Muscarella P, Wall K, Ellison C, and Bloomston M
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Gastrointestinal Neoplasms mortality, Humans, Male, Middle Aged, Morbidity, Prognosis, Survival Rate, Treatment Outcome, Gastrointestinal Neoplasms surgery, Pancreatectomy
- Abstract
Background: Pancreatectomy has a high morbidity but remains the only chance of cure for pancreatic cancer. Its efficacy for non-pancreatic malignancies is less clear. We reviewed our experience with pancreatectomy for non-pancreatic malignancies to determine outcomes and identify predictors of survival., Patients and Methods: The records of patients who underwent pancreatectomy for non-pancreatic malignancies between 1990 and 2005 were reviewed. Survival curves were constructed using the Kaplan-Meier method and compared using log-rank analysis. Cox proportional hazards was used to identify predictors of survival., Results: 29 patients (18 M/11 F) with a mean age of 59.9 years (range 29-86) underwent pancreatectomy for non-pancreatic malignancies. 19 (66%) primary malignancies were GI in origin. Most operations were undertaken with curative intent (76%), whereas the remainder was for symptom palliation. Pancreatectomy was completed for metastatic disease in 7 patients (24%) or en bloc to achieve negative margins in 22 patients (76%). Complete (i.e., R0) resection was achieved in 17 (59%). Perioperative mortality was 3%. Median follow-up was 15 months (range 7-172). Median overall survival was 12 months with 1-year survival of 48%. Significant predictors of improved survival by univariate analysis were R0 resection, non-GI primary, and pancreatic metastasectomy (vs. en bloc resection). Only R0 resection was predictive of long-term survival by multivariate analysis (median 21 months vs. 6)., Conclusion: Pancreatic resection for non-pancreatic malignancies can be completed with minimal mortality. However, incomplete resection results in poor overall survival. Pancreatectomy for non-pancreatic malignancies should only be undertaken if complete resection is possible.
- Published
- 2007
- Full Text
- View/download PDF
19. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
- Author
-
Varker KA, Kondadasula SV, Go MR, Lesinski GB, Ghosh-Berkebile R, Lehman A, Monk JP, Olencki T, Kendra K, and Carson WE 3rd
- Subjects
- Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell metabolism, Carcinoma, Renal Cell secondary, Gene Expression Regulation, Neoplastic drug effects, Humans, Immunoblotting, Kidney Neoplasms drug therapy, Kidney Neoplasms immunology, Killer Cells, Natural metabolism, Melanoma drug therapy, Melanoma immunology, Monocytes metabolism, Phosphorylation drug effects, Reverse Transcriptase Polymerase Chain Reaction, STAT5 Transcription Factor drug effects, Signal Transduction, Skin Neoplasms drug therapy, Skin Neoplasms metabolism, Skin Neoplasms secondary, T-Lymphocytes metabolism, Antineoplastic Agents therapeutic use, Flow Cytometry, Interleukin-2 therapeutic use, Kidney Neoplasms metabolism, Melanoma metabolism, STAT5 Transcription Factor blood
- Abstract
Purpose: Treatment with interleukin (IL)-2 (Proleukin) yields a 10% to 20% response rate in patients with metastatic melanoma or metastatic renal cell carcinoma. IL-2 is known to activate distinct signals within lymphocytes, including the Janus-activated kinase-signal transducer and activator of transcription (STAT) pathway. We examined the phosphorylation of STAT5 (P-STAT5) in IL-2-stimulated immune cells of normal subjects and in patients receiving IL-2 therapy using a novel flow cytometric assay to characterize the pattern and level of activation within immune subsets., Experimental Design: Normal peripheral blood mononuclear cells (PBMC) were treated in vitro with IL-2 and analyzed for P-STAT5 using an intracellular flow cytometric assay. PBMC were simultaneously evaluated for the induction of STAT5-regulated genes at the transcript level. PBMC were also obtained from patients immediately before and 1 hour after treatment with high-dose IL-2 and analyzed for the presence of P-STAT5 within immune cell subsets by dual-variable intracellular flow cytometry., Results: In vitro IL-2 treatment produced a rapid and dose-dependent increase in P-STAT5 within normal PBMC that correlated with the induction of transcript for the IL-2-responsive genes CIS, Pim-1, and SOCS1 (correlation coefficients 0.8628, 0.6667, and 0.7828, respectively). Dose-dependent induction of P-STAT5 was detected in PBMC for up to 18 hours following in vitro pulse stimulation with IL-2. P-STAT5 was detected within a subset of normal donor CD4(+) T cells (52.2 +/- 15.0%), CD8(+) T cells (57.6 +/- 25.8%), and CD56(+) natural killer (NK) cells (54.2 +/- 27.2%), but not CD14(+) monocytes or CD21(+) B cells, following in vitro IL-2 treatment. The generation of P-STAT5 within immune cell subsets after the therapeutic administration of IL-2 varied significantly between individuals. NK cells were noticeably absent in the posttreatment sample, a finding that was consistent for all patients examined. Surprisingly, activated STAT5 persisted within CD4(+) and CD8(+) T lymphocytes, as well as CD56(+) NK cells, for up to 3 weeks post-IL-2 treatment in three patients who exhibited a clinical response to therapy and in a fourth who exhibited a significant inflammatory response after 11 doses of therapy (first cycle)., Conclusions: The flow cytometric assay described herein is a highly efficient and reliable method by which to assess the cellular response to IL-2 within PBMC and specific immune effector subsets, both in vitro and in the clinical setting. Assessment of P-STAT5 in patient PBMC in response to therapeutic IL-2 administration reveals disparate responses between immune cell subsets as well as interpatient variation. Persistent activation of STAT5 within NK and T cells was an unexpected observation and requires further investigation.
- Published
- 2006
- Full Text
- View/download PDF
20. The small GTPase RhoA has greater expression in small cell lung carcinoma than in non-small cell lung carcinoma and contributes to their unique morphologies.
- Author
-
Varker KA, Phelps SH, King MM, and Williams CL
- Subjects
- ADP Ribose Transferases genetics, ADP Ribose Transferases metabolism, Adenocarcinoma enzymology, Adenocarcinoma genetics, Adenocarcinoma pathology, Adenosine Diphosphate Ribose metabolism, Botulinum Toxins genetics, Botulinum Toxins metabolism, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Small Cell genetics, Carcinoma, Small Cell pathology, Carcinoma, Squamous Cell enzymology, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell pathology, Cell Adhesion, Cell Division drug effects, Cell Size, Cyclin-Dependent Kinase Inhibitor p21, Cyclins biosynthesis, Cyclins genetics, DNA, Complementary genetics, Gene Expression Regulation, Neoplastic, Guanosine 5'-O-(3-Thiotriphosphate) pharmacology, Humans, Lung Neoplasms genetics, Lung Neoplasms pathology, Neoplasm Metastasis, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins biosynthesis, Neoplasm Proteins genetics, Signal Transduction drug effects, rhoA GTP-Binding Protein antagonists & inhibitors, rhoA GTP-Binding Protein biosynthesis, rhoA GTP-Binding Protein genetics, Carcinoma, Non-Small-Cell Lung enzymology, Carcinoma, Small Cell enzymology, Lung Neoplasms enzymology, Neoplasm Proteins physiology, rhoA GTP-Binding Protein physiology
- Abstract
The two major forms of lung carcinoma, small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC), are clinically distinct, and are also differentiated by morphology and behavior in culture. SCLC cells have a greater metastatic potential than NSCLC cells in vivo, and exhibit a unique spherical morphology in culture due to their inability to adhere and spread on the substratum. Because the small GTPase RhoA affects metastatic properties and regulates cell morphology, we examined whether differences in RhoA expression and activity contribute to the distinct SCLC and NSCLC phenotypes. We found that the expression and GTPgammaS-dependent activation of RhoA are generally greater in SCLC cell lines (SCC-9, NCI-H69, NCI-H146, and NCI-H345) than in NSCLC cell lines (NCI-H23, NCI-H157, NCI-H520, and NCI-H522). The effects of inhibiting Rho-mediated signaling in these cells were investigated by transfecting the cells with cDNA coding for C3 exoenzyme, which ADP-ribosylates and inactivates Rho. Expression of C3 exoenzyme in SCLC cells induces cell-cell compaction, and causes NCI-H345 cells to adhere and spread on collagen IV. In contrast, expression of C3 exoenzyme in NSCLC cells does not induce detectable compaction, but induces cell spreading of NCI-H23 and NCI-H157 cells. Cell proliferation is diminished by Rho inactivation in the majority of the NSCLC cell lines, but not the SCLC cell lines. Expression of p21Cip1/WAF1 is also diminished by Rho inactivation in two of the SCLC cell lines, but is not significantly altered in the NSCLC lines. These results indicate that Rho-mediated signaling may regulate different events in SCLC and NSCLC cells, including adhesion of SCLC cells and proliferation of NSCLC cells.
- Published
- 2003
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.